Daewoong Pharmaceutical Co., Ltd

A069620

KR7069620003

Daewoong Pharma is a Korea-based company principally engaged in the manufacture and distribution of pharmaceuticals. The Company's products mainly include antihypertensive drugs, antianemic agents, antidiabetic agents, antiemetic agents, antihistamine agents, antimicrobials, antineoplastics, antiobesity agents, antipyretic agents, analgesic agents, anti-inflammatory agents, biosimilars, remedies for bone and joint diseases, cardiovascular treatments, central nervous system treatments, digestive agents, dermatologic agents, gastrointestinal agents, health supplements and respiratory remedies, among others. The Company distributes its products in domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Daewoong Pharmaceutical Co., Ltd

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
DAEWOONG PHARMACEUTICAL CO., LTD	-3.85%	925M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+17.88%	44.31B
OTSUKA HOLDINGS CO., LTD.	+19.87%	22.17B
SANDOZ GROUP AG	+13.05%	14.62B
CIPLA LIMITED	+8.06%	13.12B
ZYDUS LIFESCIENCES LIMITED	+39.21%	11.58B
ONO PHARMACEUTICAL CO., LTD.	-8.96%	6.96B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+6.50%	5.03B

Generic Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
112,300 ^KRW	+1.35%		-0.35%	-3.85%

Apr. 12	AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd	CI
Mar. 19	AEON Biopharma, Inc. announced that it expects to receive $15 million in funding from Daewoong Pharmaceutical Co., Ltd	CI

AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd	Apr. 11	CI
AEON Biopharma, Inc. announced that it expects to receive $15 million in funding from Daewoong Pharmaceutical Co., Ltd	Mar. 18	CI
Daewoong Pharmaceutical Secures Approval for Stem Cell Processing Facility in Indonesia	Feb. 15	MT
Zydus Worldwide DMCC and Daewoong Pharmaceutical Co., Ltd. Announces Exclusive Licensing Agreement for Development and Commercialization of Leuprolide Long-Acting Injectable in the U.S	Dec. 10	CI
Daewoong pharmaceutical Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative GLP-1 Obesity Treatment with Advanced Microneedle Technology for Sustained Weekly Efficacy	Nov. 06	CI
P.T. SELATOX BIO PHARMA announced that it expects to receive IDR 200 billion in funding from Daewoong pharmaceutical Co.,Ltd	23-10-26	CI
Daewoong Therapeutics Gets Mfds Nod for Phase 1 Ind for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema	23-09-25	CI
Hyphens Pharma Unit to Distribute Daewoong Pharmaceutical's Nabota Botox in Malaysia	23-08-30	MT
Hyphens Pharma International Limited Announces Successful Registration in Malaysia	23-08-30	CI
Daewoong pharmaceutical Co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Daewoong Pharmaceutical's Nabota Surpasses 600,000 Customers in the US	23-08-02	MT
Daewoong Pharmaceutical Enters into License and Distribution Agreement with Cooper Pharma	23-07-24	CI
AEON Biopharma, Inc. completed the acquisition of Priveterra Acquisition Corp. from Priveterra Sponsor, LLC, Empyrean Capital Overseas Master Fund, Ltd., managed by Empyrean Capital Partners, LP, Medy-Tox Inc., Daewoong pharmaceutical Co.,Ltd, Strathspey Crown LLC and others in a reverse merger transaction.	23-07-20	CI
Daewoong Pharmaceutical Obtains Approval for SGLT2i + Metformin Combination Drug Envlomet	23-07-18	CI
Vincere Biosciences Inc announced that it has received funding from Hanall Biopharma Co., Ltd., Daewoong pharmaceutical Co.,Ltd	23-06-11	CI
Daewoong Pharmaceutical Regaining Rights to Fexuprazan in the United States and Canada Upon Termination of License Agreement with Neurogastrx	23-06-05	CI
Avacta Group Plc acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd.	23-06-04	CI
Daewoong Pharmaceutical Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023	23-05-19	CI
Daewoong pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Daewoong pharmaceutical Co.,Ltd's Envlo to Enter the Global Market in Full Swing with Filing for Product License in Three Asean Countries	23-03-22	CI
Daewoong pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-08	CI
M8 Pharmaceuticals and Daewoong Pharmaceutical Strengthens Strategic Partnership by Signing an Exclusive Licensing Agreement for Envlo (Enavoglifozin) for Brazil and Mexico	23-02-28	CI
Daewoong Pharmaceutical Begins the First Administration of Bersiporocin	23-02-06	CI
Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea	23-01-31	CI

Daewoong Pharmaceutical Co., Ltd

Equities